0743 GMT - Novo Nordisk's CEO departure suggests another profit warning is highly possible, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. Consensus estimates for sales of the Danish pharma giant's Ozempic diabetes drug this year look too high, as new prescriptions have now turned negative, the analysts say. Meanwhile, Intron's expectations that sales of the Wegovy obesity drug will reach an inflection point thanks to a deal with CVS Health and the anticipated end of sales of compounded versions is likely a best-case scenario, the analysts say. "Furthermore, following Friday's CEO news, we believe there is further risk to 2025 guidance," Intron says. Novo Nordisk earlier this month cut its full-year guidance and on Friday said CEO Lars Fruergaard Jorgensen would leave the company. Shares rise 1.9%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 20, 2025 03:43 ET (07:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。